These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15041732)

  • 1. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
    Bruns CJ; Koehl GE; Guba M; Yezhelyev M; Steinbauer M; Seeliger H; Schwend A; Hoehn A; Jauch KW; Geissler EK
    Clin Cancer Res; 2004 Mar; 10(6):2109-19. PubMed ID: 15041732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
    Solorzano CC; Hwang R; Baker CH; Bucana CD; Pisters PW; Evans DB; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 May; 9(5):1858-67. PubMed ID: 12738744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
    Amoh Y; Li L; Tsuji K; Moossa AR; Katsuoka K; Hoffman RM; Bouvet M
    J Surg Res; 2006 May; 132(2):164-9. PubMed ID: 16500746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
    Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
    Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
    Stephan S; Datta K; Wang E; Li J; Brekken RA; Parangi S; Thorpe PE; Mukhopadhyay D
    Clin Cancer Res; 2004 Oct; 10(20):6993-7000. PubMed ID: 15501979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
    Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
    Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
    BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
    Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
    Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
    Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
    Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
    Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
    Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
    Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer.
    Xu L; Qin Y; Huang J; Qin J; Gu J; Zhu H; Liu H; Cai Y; Wu X; Feng J
    Anticancer Drugs; 2013 Apr; 24(4):406-14. PubMed ID: 23411684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
    Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ
    Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
    Jia L; Zhang MH; Yuan SZ; Huang WG
    World J Gastroenterol; 2005 Jan; 11(3):447-50. PubMed ID: 15637766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.